© Moffitt Cancer Center
Bio-Linked™ is seeking blood donors to help advance cancer studies. The Blood Institute is collaborating with Moffitt Cancer Center in Florida to collect mononuclear cells for cancer research and treatments. Mononuclear cells play a critical role in healthy immune function and prevention of cancer. These cells are separated and extracted from whole blood during apheresis blood donation, a process that takes a bit longer than a typical platelet donation (approximately 120 minutes). Donors who participate should be healthy adults who weigh at least 110 pounds and meet all criteria for a whole blood donation. Participants are eligible to receive compensation.
In order to participate, donors must also accept research opportunities on their BioProfile on the Bio-Linked website. Under preferences, be sure to note your preferred method of contact, and mark “Donate Apheresis White Blood Cells” on the slide for donation types you are willing to offer.
Moffitt, a non-profit, National Cancer Institute-designated treatment and research center, has operated in Tampa, Florida, since 1986. It conducts groundbreaking studies to fight many forms of cancer, in five focal areas: cancer biology & evolution, cancer epidemiology, chemical biology & molecular medicine, health outcomes & behavior, and immunology.
Through Bio-Linked™ and Bio-Sharing™, the Blood Institute provides the blood cells necessary to support Moffitt’s cutting-edge cell therapy research and development— programs that could lead to discoveries of new cancer treatments and cures. The mononuclear cell is a key ingredient for the cancer-fighting lymphocyte drugs Moffitt Cancer Center creates with the help of drug developers. These innovative treatments give hope to patients with previously untreatable cancers.
By participating in Bio-Linked™, you are part of the pioneering relationship between the Blood Institute and Moffitt Cancer Center, and you are helping evolve the search for cures to cancers that affect your family members, friends, neighbors, and millions of others.
Read more news from Bio-Linked™
Subscribe to our quarterly newsletter